Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENC...
Elmentve itt :
| Szerzők: |
Mahaffey Kenneth W. Jardine Meg J. Bompoint Severine Cannon Christopher P. Neal Bruce Heerspink Hiddo J.L Charytan David M. Edwards Robert Agarwal Rajiv Bakris George Bull Scott Kollaborációs szervezet: REDENCE Study Investigators Keltai Katalin Takács Róbert et al |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | CIRCULATION
140 No. 9 |
| Tárgyszavak: | |
| doi: | 10.1161/CIRCULATIONAHA.119.042007 |
| mtmt: | 31086950 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/26652 |
Hasonló tételek
-
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Szerző: Perkovic Vlado, et al.
Megjelent: (2019) -
The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics
Szerző: Jardine Meg J., et al.
Megjelent: (2017) -
Cardiovascular system diuretic drugs /
Szerző: Leprán István -
The pathophysiology of cardiovascular diseases systemic arterial hypertension ; cardiac failure /
Szerző: Szabó Gyula, et al. -
Cardiovascular health of patients with cancer Challenges abound /
Szerző: Chan Jeffrey Shi Kai, et al.
Megjelent: (2025)